스콜라락 홀딩 코퍼레이션(SRRK)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $46.65 (-4.83%), 시가총액 $6.14B, 52주 최저~최고 $27.92 ~ $51.28.
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial f
스콜라락 홀딩 코퍼레이션의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
스콜라락 홀딩 코퍼레이션의 현재 주가는 $46.65 (-4.83%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
스콜라락 홀딩 코퍼레이션의 시가총액은 약 $6.14B입니다.
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromu